12,372 trials
Heart Failure · Respiratory Insufficiency · Stroke Acute
Primary: Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee…
Multiple Sclerosis, Relapsing-Remitting
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 18; 2 participants
Cervical Cancer · Vulvar Cancer · Vaginal Cancer
Primary: Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type — 787.8; 638.4; 598.7; 453.5 mMU/mL — p=< 0.001
Colorectal Neoplasms
Primary: Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment — 58.5; 18.7; 12.2; 2.4…
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.4 percentage of participants
Relapsed and Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Independent Review Committee — 35.8 percentage of participants
Nonproliferative Diabetic Retinopathy
Primary: Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8…
Diabetes Mellitus, Type 2 · Diabetic Nephropathy
Primary: Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End-stage Kidney Disease (ESKD), and Renal or Cardiovascular (CV) Death — 61.24; 43.21 Event rate per…
Short Bowel Syndrome
Primary: Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 — -4.92 Liter per week (L/week)
HIV-1-infection
Primary: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm — 0.4; 1.1 percentage of participants — p=0.37
Esophageal Carcinoma · Esophagogastric Junction Carcinoma
Primary: Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus — 8.2; 7.1 Months — p=0.00894
Spondyloarthritis
Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 18.4; 35.6; 48.1; 51.8 percentage of participants…
Ovarian Cancer
Primary: Overall Survival (OS) — 11.8; 15.7; 13.1 months — p=0.8253
HIV
Primary: Number of Patients Virologically Suppressed (HIV RNA <50 Copies/ml) at 48 Weeks. — 5 Participants
NTM Lung Infection Due to MAC
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 68; 90; 20; 32 participants